 This is an open-label, randomized, multicenter, comparative, and parallel-group study comparing the therapeutic effects of two interferon-beta-1a regimens in relapsing-remitting multiple sclerosis MS. The primary objective is to demonstrate the superiority of Rebif 44 microgram mcg subcutaneous injection given three times a week 132 mcg per week to that of Avonex 30 mcg intramuscular injection given once a week. 